ARTHUR-D.-LITTLE
2.6.2020 10:02:12 CEST | Business Wire | Press release
Arthur D. Little (ADL) today announced the acquisitions of Cutter Consortium, a business technology research company based in the US, and Presans, a leading player in industrial open innovation based in France. By combining its own expertise with an existing community of independent experts, ADL expands its consulting ecosystem to establish a next-generation value proposition powered by open consulting and open problem solving.
Cutter Consortium (www.cutter.com ) helps organizations navigate digital disruption of business models and leverage emerging technologies for competitive advantage and mission success. Through its research, consulting, training, and executive education – all delivered by globally recognized thought leaders – Cutter delivers innovative solutions to its thousands of clients worldwide. Cutter’s experts have done the ground-breaking work in areas ranging from digital architectures to digital tech, enterprise agility to data analytics, and digital leadership to sustainable innovation. At the heart of its business is a membership service that gives clients valuable access to its experts and their insight.
Presans (www.presans.com ) is a leading data-driven platform dedicated to industrial open innovation and open problem solving. Thanks to cutting-edge technology based on big data and artificial intelligence, as well as a team of fellows (former research and innovation executives) with in-depth knowledge in innovation, Presans leverages a network of over 6 million experts worldwide. Presans provides a variety of high-end open innovation services, contributing to the acceleration of decision-making and removal of scientific and technological roadblocks. Presans has worked for 50+ international industrial groups and delivered more than 100 innovation projects in Europe, the US and the Middle East.
“Arthur D. Little applies an ‘open consulting’ and ‘open problem solving’ approach and brings the best global experts to every assignment to complement its internal strengths,” comments Ignacio García Alves, Chairman and CEO of Arthur D. Little . “We believe the future is open consulting. With the double acquisition of Cutter and Presans, we are able to expand our open consulting ecosystem and open problem solving capabilities, offering access to experts, premium insight and a differentiated experience for our clients, in a seamless way.”
“The Cutter team felt an instant synergy with our colleagues at ADL. We share a focus on innovation, which, in ADL’s case, goes back to its roots, and an emphasis on providing custom, leading-edge solutions. Moreover, ADL’s more than 40 offices in 30 countries has given Cutter an enhanced ability to assist its clients worldwide,” says Karen Coburn, CEO of Cutter Consortium .
“Since its inception at the École Polytechnique's start-up incubator, Presans has always engaged with the best experts in the world, mainly to help its customers solve complex technical problems,” says Albert Meige, Founder of Presans . “Presans now addresses more and more problems at the crossroads of strategy consulting and scientific & technical expertise. The time had therefore come for Presans to strengthen itself by joining forces with Arthur D Little.”
Together with Cutter and Presans, ADL reinforces its position on digital and information technologies, as well as industrial innovation, particularly in breakthrough innovation and convergence problem solving. In addition, through the acquisition of the technological platform of Presans, ADL is accelerating its investments in artificial intelligence and machine learning to develop state-of-the-art offerings for its clients.
Cutter Consortium and Presans will continue to operate under their current brands with the same management teams, while benefiting from ADL’s capabilities, investment, and global exposure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom